Phase I/II Study of IPN01195 in Advanced Solid Tumours with MAPK Alterations

Ipsen is evaluating IPN01195—a MAPK1 inhibitor—as monotherapy in adults with advanced solid tumours (with MAPK alterations) who have no standard care options. The study includes a dose-escalation phase to determine the appropriate dosage (PADR), followed by a randomization phase comparing two doses to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumour activity.